Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q2 2021 · 10-Q
Revenue$3.08B$3.08B+53.6% vs Q2 2020 Net Income$186.00M$186.00MN/M vs Q2 2020 EPS Diluted$0.12$0.12N/M vs Q2 2020 Gross Profit$2,132,000,000+75.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$643,000,000+139.0% Free Cash Flowderived$537,000,000+167.2% Margins · derivedGross margin69.3%+8.8 pt vs Q2 2020
Operating margin8.5%+12.1 pt vs Q2 2020
Net margin6.0%+13.4 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 6, 2021 · 37 d after period end